Haduvio’s Promising Efficacy in RCC Drives Buy Rating and Increased Price Target

Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on Trevi Therapeutics (TRVI – Research Report). The associated price target was raised to $11.00.

Faisal Khurshid has given his Buy rating due to a combination of factors, primarily centered around the promising data from the RIVER study in refractory chronic cough (RCC). The study results highlighted Haduvio’s impressive efficacy, which exceeded investor expectations, particularly in both moderate and severe subtypes of RCC.
The data showed a significant reduction in 24-hour cough frequency, with a 57% placebo-adjusted reduction at the 108mg BID dose. This level of efficacy is unprecedented in RCC, making Haduvio a standout candidate in the field. Additionally, the rapid onset of efficacy and favorable patient-reported outcomes further support the potential of Haduvio, justifying the increased price target to $11 from $7.

In another report released today, Needham also maintained a Buy rating on the stock with a $25.00 price target.